Rate of incidental central nervous system meningioma detected in patients undergoing 18F-fluciclovine PET/CT imaging for evaluation of prostate cancer

Research output: Contribution to journalArticlepeer-review


Objective To evaluate the rate of incidental detection of central nervous system (CNS) meningioma in patients undergoing 18F-fluciclovine PET/computed tomography (CT) imaging for the evaluation of prostate cancer. Methods The reports of 850 18F-fluciclovine PET/ CT scans in 566 patients with pathologically proven prostate cancer performed from April 2017 to July 2019, were retrospectively reviewed for the presence of CNS meningioma. Results A total of 14 patients (2.8%) (age range: 54–82years old) had abnormal focal intracranial 18F-fluciclovine uptake, all extra-axial in location (SUVmax range: 3.2–19.3). Two cases out of 14 (0.35%) were diagnosed as metastatic lesions. Twelve out of the 14 patients, had 18F-fluciclovine PET/CT imaging findings suspicious for CNS meningioma, 2 of them received another diagnosis on further imaging, and only 10 cases (2%) had the diagnosis of meningioma according to follow-up MRI and 18F-fluciclovine PET/CT. Conclusion Focal 18F-fluciclovine avid intracranial lesions incidentally detected in patients undergoing PET/ CT imaging for prostate cancer are most often CNS meningiomas.

Original languageEnglish (US)
Pages (from-to)755-762
Number of pages8
JournalNuclear medicine communications
StateAccepted/In press - 2021


  • F-fluciclovine
  • Intracranial
  • Meningioma
  • PET/computed tomography
  • Prostate cancer

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging


Dive into the research topics of 'Rate of incidental central nervous system meningioma detected in patients undergoing <sup>18</sup>F-fluciclovine PET/CT imaging for evaluation of prostate cancer'. Together they form a unique fingerprint.

Cite this